Psoriasis Drugs - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2026-2031)

The psoriasis drugs market size is expected to grow from USD 20.05 billion in 2025 to USD 21.78 billion in 2026 and is forecast to reach USD 32.94 billion by 2031 at 8.63% CAGR over 2026-2031. This report is Segmented by Treatment Modality (Biologic Drugs, Small-Molecule Systemic Drugs, and More), Drug Class (TNF-Α Inhibitors, and More), Route of Administration (Parenteral, Oral, Topical), Distribution Channel (Hospital Pharmacies, and More), and Geography (North America, Europe, Asia-Pacific, Middle East & Africa, South America). The Market Forecasts are Provided in Terms of Value (USD).

Global Psoriasis Drugs Market Trends and Insights

Increasing Disease Burden and Demand for Psoriasis Medicines in Emerging Economies

Improved infrastructure, payer reforms, and greater disease awareness are unlocking sizable therapy demand across China, India, Brazil, and the Gulf. China’s regulator shortened innovative-drug review from two years to six months, enabling 40 novel approvals in 2023, including multiple psoriasis biologics. Brazil’s biosimilar prescriptions expanded 43% in 2023, underscoring affordability benefits for adalimumab and etanercept. India is moving in parallel; Biocon’s ustekinumab biosimilar matched Stelara efficacy at a fraction of the cost. Although stigma and underdiagnosis persist, AI-enabled dermatology platforms now achieve 89% diagnostic accuracy, helping clinicians close the treatment gap. Collectively, these factors add momentum to the psoriasis drugs market while addressing longstanding unmet needs.

Increasing Use of Combination Therapies

Clinicians are pairing injectable biologics with oral JAK1 or TYK2 inhibitors to heighten response durability in recalcitrant plaques and joint symptoms. A multi-center case series reported pronounced improvements when such dual mechanisms were employed, especially in difficult-to-treat phenotypes. Mechanistically, simultaneous blockade of IL-23/Th17 and JAK-dependent cytokine cascades yields broader inflammatory control. Retrospective analysis of 5,932 courses showed superior drug-survival for combination regimens versus monotherapy. Network meta-analysis indicates that efficacy gains are highest when mechanisms are complementary rather than duplicative, informing future trial designs. The convergence of real-world and controlled evidence is accelerating guideline inclusion and fueling innovation in co-formulated products.

Adverse Side Effects of Existing Medications

Biologic labels caution about serious infections such as tuberculosis, compelling robust pre-treatment screening and ongoing monitoring that inflate costs and deter some prescribers. JAK inhibitors faced FDA safety communications linking them to cardiovascular and malignancy risks; TYK2 selectivity may ease but not erase such concerns. Elderly patients and those with multiple comorbidities remain especially vulnerable, driving discontinuation rates of 20-30% within a year. Although topical agents offer favourable safety, limited depth of response in moderate-to-severe disease restricts their utility. Until pipelines deliver equally potent yet safer options, safety-related attrition will temper the psoriasis drugs market growth.

Other drivers and restraints analyzed in the detailed report include:

• Increase in Psoriasis Research and Pipeline Drugs
• Accelerated Approvals for First-in-Class TYK2 Inhibitors
• High Cost of Psoriasis Treatments

Segment Analysis

Biologic therapies captured 47.05% of 2025 revenue, confirming their centrality in achieving high PASI clearance for moderate-to-severe patients. Bimekizumab, the first dual IL-17A/IL-17F inhibitor, delivered 85-91% clear or almost clear skin at week 16, sustaining the biologic edge in efficacy. Meanwhile, small-molecule systemic agents form the fastest-growing modality at a 14.94% CAGR through 2031, decisive for the broader psoriasis drugs market. Precision-medicine diagnostics from Mindera Health that forecast biologic response may decrease trial-and-error cycles and bolster long-term adherence.

Combination regimens integrating oral TYK2 or JAK1 inhibitors with injectables are rewriting treatment sequences, particularly for refractory phenotypes. Real-world data show improved drug-survival and functional scores versus monotherapy. Oral innovation, epitomised by icotrokinra’s macrocyclic peptide backbone, points to a future where high-potency blockade can be delivered without needles. As formulary committees recognise these convenience gains, the psoriasis drugs market size attributed to small molecules should expand steadily.

TNF-α blockers held 40.84% market share in 2025, but multiple adalimumab biosimilars now undercut originator prices and are eroding volume. IL-17 agents are rising at a 12.31% CAGR on speed-to-response, with ixekizumab and brodalumab shaving weeks off PASI milestones. IL-23 inhibitors like guselkumab and risankizumab continue gaining traction through sustained clearance rates and convenient quarterly dosing. Otherwise, niche mechanisms PDE4, TYK2, and IL-36 inject diversity that supports long-term resilience for the psoriasis drugs industry.

Biosimilar entry is slashing reference-product costs by up to 90%, aiding health systems but squeezing innovator margins. Competitive intensity centres on differentiation claims such as rapidity, durability, or extra-cutaneous benefits. Emerging TYK2 contenders like ESK-001 hope to surpass deucravacitinib in terms of the magnitude and duration of response, potentially shifting class hierarchies.

Complete Report Scope:

• By Treatment Modality
  • Biologic Drugs
  • Small-molecule Systemic Drugs
  • Topical Agents
  • Combination Regimens
• By Drug Class
  • TNF-α Inhibitors
  • IL-12/23 Inhibitors
  • IL-17 Inhibitors
  • IL-23 Inhibitors
  • PDE4 Inhibitors
  • TYK2 Inhibitors
  • Other Classes
• By Route of Administration
  • Parenteral
  • Oral
  • Topical
• By Distribution Channel
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
• By Geography
  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • Germany
    • United Kingdom
    • France
    • Italy
    • Spain
    • Rest of Europe
  • Asia-Pacific
    • China
    • Japan
    • India
    • Australia
    • South Korea
    • Rest of Asia-Pacific
  • Middle East & Africa
    • GCC
    • South Africa
    • Rest of Middle East & Africa
  • South America
    • Brazil
    • Argentina
    • Rest of South America

Geography Analysis

North America generated the highest revenue with market share of 37.31% in 2025, buoyed by advanced insurance coverage, proactive screening, and rapid FDA approvals, which accelerate uptake of first-in-class agents like TYK2 inhibitors. Psoriasis affected 7.9 million US adults in 2023, with heightened prevalence among individuals with BMI ≥30, reinforcing the obesity-linked demand surge. Biosimilar competition, notably multiple ustekinumab alternatives launching at deep discounts, is reshaping price dynamics while maintaining volume momentum.

Europe follows as the second-largest region, supported by the EMA’s centralised review, robust dermatologist networks, and growing biosimilar trust that lowers costs and can speed patient onboarding. Health technology assessments across Germany, France, and the UK increasingly prioritise real-world outcomes, compelling manufacturers to support value-based contracting. The post-Brexit regulatory split obliges companies to maintain dual frameworks yet has not materially slowed access, keeping the psoriasis drugs market competitive across major European economies.

Asia-Pacific remains the fastest-growing geography with 9.03% CAGR between 2026 and 2031. China leads regional expansion thanks to streamlined NMPA reviews, fast reimbursement listings, and domestic innovation exemplified by Xeligekimab. Japan consistently demonstrates high biologic utilisation and swift adoption of global breakthroughs, with deucravacitinib showing cross-ethnic efficacy. India’s biosimilar leadership and improving payer systems are broadening affordability. Australia and South Korea offer mature infrastructures where reduced patient copays have meaningfully lifted biologic penetration. Collectively, the heterogeneity of Asia-Pacific nations delivers a sizeable incremental lift to the psoriasis drugs market.

List of Companies Covered in this Report:

• Abbvie
• Johnson & Johnson
• Novartis
• Eli Lilly and Company
• Amgen
• UCB
• Bristol-Myers Squibb
• Pfizer
• Sun Pharmaceuticals Industries
• Boehringer Ingelheim Intl. GmbH
• Leo Pharma
• Dr. Reddy’s Laboratories Ltd.
• Takeda Pharmaceuticals
• Incyte
• Almirall S.A.
• Dermavant Sciences Ltd.
• Arctic Bioscience AS
• Qyuns Therapeutics Co., Ltd.
• Sanofi
• Glenmark Pharmaceuticals

Additional Benefits:

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support